Zacks Investment Research downgraded shares of EpiCept Corp (EPCT) from OUTPERFORM to NEUTRAL on May 10, 2012, with a target price of $1.00.
EpiCept is a commercial stage specialty pharmaceutical company targeting cancer and pain markets. The Company's lead cancer candidate Ceplene has been already approved in EU and Israel for the remission maintenance of AML and a pivotal trial is approved in the US. Another important candidate is AmiKet for peripheral neuropathy, which is approved for Phase III trial. The Company has engaged SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize its shareholder value, which include possible sale of the Company. We are Neutral at this point of time on EpiCept shares.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EpiCept Corp (EPCT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment